Hsieh, Hsiao-Yen <br/><br/>
Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways.  [electronic resource] 

 -  Cancer letters  Jan 2016 
 - 56-65 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2015.09.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiopoietin-Like Protein 4<br/>Angiopoietins--genetics<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Cyproheptadine--pharmacology<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Glycogen Synthase Kinase 3--antagonists & inhibitors<br/>Glycogen Synthase Kinase 3 beta<br/>Humans<br/>Mice<br/>Mice, Inbred BALB C<br/>Receptors, Serotonin--analysis<br/>Signal Transduction--drug effects<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Tuberous Sclerosis Complex 2 Protein<br/>Tumor Suppressor Proteins--physiology<br/>Urinary Bladder Neoplasms--drug therapy<br/>beta Catenin--antagonists & inhibitors